Key facts
- Qnovia’s last known valuation is $250.0M (Dec 2024).
- It has raised $43.5M across 2 recorded rounds; the latest was Early Stage VC ($14.2M) in Oct 2024.
- Notable investors include Gaingels, Evolution VC Partners, Sand Hill Angels, DG Ventures, DG Ventures (Tokyo) — 11 tracked in total.
- Qnovia has filed 2 Form Ds with the SEC since 2023, most recently Nov 2024 ($14.2M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Qnovia
Funding rounds
2 roundsAbout Qnovia
Developer of a drug delivery platform designed to advance pharmaceutical research and treatments aimed at saving lives. The company's platform offers an inhalation-based technology that addresses many of the limitations of traditional pharmaceutical drug delivery systems to improve patient outcomes that optimize human factors and tackle critical medical challenges, enabling patients to get a variety of new inhaled therapies and improve health.
- Sector
- Healthcare
- HQ
- Richmond, VA, United States
- Founded
- 2018
- Employees
- 8
- Website
- qnovia.com/
- Ownership
- Privately Held (backing)
Qnovia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qnovia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qnovia in its N-PORT filings yet. We sweep new filings monthly.